(Q38598524)

4 September 2017

Disease kinetics for decision-making in advanced melanoma: a call for scenario-driven strategy trials (English)

1 reference

4 September 2017

1 reference

1

Jean Jacques Grob

0 references

Dirk Schadendorf

series ordinal

3

object named as

Dirk Schadendorf

1 reference

4 September 2017

4

Keith Flaherty

1 reference

4 September 2017

2

Georgina V Long

1 reference

4 September 2017

Jean Jacques Grob

1

1 reference

4 September 2017

1 October 2015

1 reference

Lancet Oncology Commission

4 September 2017

1 reference

4 September 2017

16

1 reference

4 September 2017

13

1 reference

4 September 2017

e522-6

1 reference

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

4 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900003-0

7 January 2021

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900003-0

7 January 2021

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900003-0

7 January 2021

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900003-0

7 January 2021

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900003-0

7 January 2021

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900003-0

7 January 2021

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900003-0

7 January 2021

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900003-0

7 January 2021

An evidence-based staging system for cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900003-0

7 January 2021

Serum S100B, lactate dehydrogenase and brain metastasis are prognostic factors in patients with distant melanoma metastasis and systemic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900003-0

7 January 2021

Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900003-0

7 January 2021

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900003-0

7 January 2021

The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900003-0

7 January 2021

[Management of patients with metastatic cutaneous melanoma: French national guidelines. French National Cancer Institute].

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900003-0

7 January 2021

Do BRAF inhibitors select for populations with different disease progression kinetics?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900003-0

7 January 2021

Initial metastatic kinetics is the best prognostic indicator in stage IV metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900003-0

7 January 2021

Improved overall survival in melanoma with combined dabrafenib and trametinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900003-0

7 January 2021

10.1016/S1470-2045(15)00003-0

Identifiers

DOI

1 reference

4 September 2017

1 reference

PubMed ID

26433825